Feature | TCT | November 09, 2017

TCT 2017 Late-breaking Clinical Trial Presentations

TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.

November 9, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has selected 12 late-breaking clinical trials and 16 first report Investigations that are guaranteed to impact patient care and future directions in cardiovascular technologies.

Monday, October 30 - Main Arena I

Late-Breaking Clinical Trials 1

• CULPRIT-SHOCK: A Randomized Trial of Multivessel PCI in Cardiogenic Shock. Presenter is Holger Thiele.

• EXCEL QOL: Quality of Life After PCI vs. CABG in Left Main Coronary Artery Disease. Presenter is Suzanne J. Baron.

• DKCRUSH-V: A Randomized Trial of Double Kissing Crush vs. Provisional Stenting for Treatment of Distal Left Main Bifurcation Lesions. Presenter is Shao-Liang Chen.

First Report Investigations 1

• HREVS: A Randomized Trial of PCI vs. CABG vs Hybrid Revascularization in Patients With Coronary Artery Disease. Presenter is Vladimir Ganyukov.

• HARMONEE: A Randomized Trial of a Bioabsorbable Polymer-Based DES With a Luminal CD34+ Antibody Coating vs. a Durable Polymer-Based DES in Patients With Coronary Artery Disease. Presenter is Shigeru Saito.

• DARE: A Randomized Trial of a Drug-Eluting Balloon vs. a Metallic DES in Patients With Coronary Artery In-Stent Restenosis. Presenter is Jose P.S. Henriques.

• VAMPIRE 3: A Randomized Trial of Distal Filter Protection During PCI of High-Risk Plaque. Presenter is Kiyoshi Hibi.

Tuesday, October 31, 2017 - Main Arena II

Late-Breaking Clinical Trials 2: Co-sponsored by the Lancet

• ABSORB IV: 30-Day Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs. a Metallic DES in Patients With Coronary Artery Disease. Presented by Gregg W. Stone.

• ABSORB III: 3-Year Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease. Presented by Stephen G. Ellis.

• PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis. Presented by David J. Cohen.

First Report Investigations 2

• ABSORB II: 4-Year Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease. Presented by Bernard R. Chevalier.

• CrossBoss First: A Randomized Trial of Antegrade Dissection and Re-entry vs Standard Wire Escalation for Crossing Coronary Artery Chronic Total Occlusions. Presented by Emmanouil S. Brilakis.

• REVASC: A Randomized Trial to Assess Recovery of Left Ventricular Function After PCI of Coronary Artery Chronic Total Occlusions. Presented by Kambis Mashayekhi.

• FAVOR II China: Diagnostic Accuracy of the Angiographic Quantitative Flow Ratio (QFR) FFR-Angiography in Patients With Coronary Artery Disease. Presented by Bo Xu.

• FAVOR II Europe Japan: Diagnostic Accuracy of the Angiographic Quantitative Flow Ratio (QFR) FFR-Angiography in Patients With Coronary Artery Disease. Presented by Jelmer Westra.

Wednesday, November 1, 2017 - Main Arena III

Late-Breaking Clinical Trial 3: Co-sponsored by the Journal of the American Medical Association

• SENIOR: A Randomized Trial of a Bioabsorbable Polymer-Based Metallic DES vs. a BMS With Short DAPT in Patients With Coronary Artery Disease Older Than 75 Years. Presented by Olivier Varenne.

• DAPT STEMI: A Randomized Trial of 6-Month vs. 12-Month DAPT After DES Implantation in STEMI. Presented by Elvin Kedhi.

• REDUCE: A Randomized Trial of 3-Month vs 12-Month DAPT After Implantation of a Bioabsorbable Polymer-Based Metallic DES With a Luminal CD34+ Antibody Coating in Patients With ACS. Presented by Harry Suryapranata.

First Report Investigations 3

• MITRAL: 30-Day Outcomes of Transcatheter MV Replacement in Patients With Severe Mitral Valve Disease Secondary to Mitral Annular Calcification or Failed Annuloplasty Rings. Presented by Mayra Guerrero.

• INTREPID: 30-Day Outcomes of Transcatheter MV Replacement in Patients With Severe Mitral Regurgitation. Presented by Paul Sorajja.

• TENDYNE: 1-Year Outcomes of Transcatheter MV Replacement in Patients With Severe Mitral Regurgitation. Presented by David W.M. Muller.

• TRACER: 6-Month Outcomes of Transcatheter MV Neochordal Repair with the Harpoon System in Patients With Severe Primary Mitral Regurgitation. Presented by James S. Gammie.

• MAVERIC: 6-Month Outcomes of Transcatheter MV Repair in Patients With Severe Secondary Mitral Regurgitation. Presented by Stephen G. Worthley.

Thursday, November 2, 2017 - Main Arena IV

Late-Breaking Clinical Trials 4

• PREVAIL: 5-Year Outcomes From a Randomized Trial of Left Atrial Appendage Closure (LAA) vs. Medical Therapy in Patients With Non-Valvular Atrial Fibrillation. Presented by Vivek Y. Reddy.

• ORBITA: A Randomized, Sham-Controlled Trial of PCI in Patients With Coronary Artery Disease. Presented by Rasha Al-Lamee.

• FAME 2: 3-Year Clinical and Cost-Effectiveness Outcomes of FFR-Guided PCI in Patients With Coronary Artery Disease. Presented by William F. Fearon.

First Report Investigations 4

• TRI-REPAIR: 30-Day Outcomes of Transcatheter TV Repair in Patients With Severe Secondary Tricuspid Regurgitation. Presented by Georg Nickenig.

• FORMA: 30-Day Outcomes of Transcatheter TV Repair in Patients With Severe Secondary Tricuspid Regurgitation. Presented by Susheel K. Kodali.

Other Studies, Videos and Articles From TCT 2017

VIDEO: What Went Wrong With the Absorb Stent? – discussion on the Absorb trials at TCT 2017 with Ajay Kirtane, M.D.

Current State of Bioresorbable Stent Technology

Positive, Sustained Improvements Seen at One Year in SCOUT I With Transcatheter Tricuspid Repair

VIDEO: Transcatheter Mitral Valve Implantation in Practice and Technologies in Development

VIDEO: The Role and Responsibilities of the Cath Lab Manager

VIDEO: New Frontiers in Radial Access

VIDEO: TAVR For Asymptomatic Severe Aortic Stenosis – with Philippe Genereux, M.D.

SURTAVI and FORWARD Studies Reinforce Hemodynamic Benefits of Evolut TAVR Platform in Intermediate-Risk Patients

VIDEO: Overview of the National Cardiogenic Shock Initiative — with William W. O’Neill, M.D.

Supersaturated Oxygen Therapy Reduces Infarct Size for High-Risk Stented AMI Patients

VIDEO: How Transcatheter PFO Closure Can Reduce Cryptogenic Stroke — with John Rhodes, M.D.

VIDEO: Update of Mitral Valve Repair and Replacement Technologies — with Ted Feldman, M.D.

4C Medical's Novel Transcatheter Mitral Valve Presented at TCT 2017 Shark Tank Innovation Competition

VIDEO: Cath Lab of the Future Cardiovascular Technologies to Watch — with Juan Granada, M.D.

VIDEO: Converting to Bundled Payments for PCI — with Peter Duffy, M.D.

For more information: www.crf.org/tct/agenda/2017-late-breaking-trials-and-first-report-investigations

Links to Late-breaking Trials at Other Meetings:

SCAI 2017 Late-Breaking Clinical Trial Presentations

Heart Rhythm Society 2017 Late-Breaking Electrophysiology Trials

ACC 2017 Late-Breaking Trials

TCT 2016 Late-breaking Trials and First Reports

Log in or register to post comments

Related Content

For the first time, patients will no longer need to travel abroad for treatment of acute cardiac diseases, as the Gibraltar Health Authority prepares to provide local coronary angiography and angioplasty services in a new interventional cardiac suite

News | Cath Lab

Philips and Gibraltar Health Authority Announce 16-year Strategic Partnership, Transforming Patient Imaging and Cardiac Care at St Bernard’s Hospital

March 14, 2023 — Royal Philips, a global leader in health technology, and the Gibraltar Health Authority, announced they ...

March 14, 2023

System Leverages Next Generation DeepOCTÔ Technology and Near Infrared Spectroscopy to Optimize Coronary Stent Placement in the Cardiac Catheterization Lab

News | Cath Lab

SpectraWAVE Secures 510(k) Clearance of HyperVue Intravascular Imaging System

March 1, 2023 — SpectraWAVE, Inc., a medical imaging company focused on improving the treatment and outcomes for ...

March 01, 2023

News | Cath Lab

Innovative Health Expands into Cath Lab with Clearance to Reprocess Eagle Eye Digital IVUS Catheter

May 31, 2022 — Innovative Health, LLC, a specialty cardiology reprocessor, announced that the company has received ...

May 31, 2022

The U.S. Food and Drug Administration (FDA) has recalled the Dragonfly OpStar Imaging Catheter, and has identified this as a Class I recall, the most serious type of recall.

News | Cath Lab

Abbott Medical Recalls Dragonfly OpStar Imaging Catheter for Potential Loose Catheter Marker Band

May 26, 2022 — The U.S. Food and Drug Administration (FDA) has recalled the Dragonfly OpStar Imaging Catheter, and has ...

May 26, 2022

Celebrating the opening of new Interventional Cardiology Suite at NewYork-Presbyterian Hudson Valley Hospital

News | Cath Lab

NewYork-Presbyterian Hudson Valley Hospital Launches Interventional Cardiology Program and Opens State-of-the-Art Cardiac Catheterization Lab

April 25, 2022 – NewYork-Presbyterian Hudson Valley Hospital celebrated the launch of its interventional cardiology ...

April 25, 2022

Philips Image Guided Therapy System

News | Cath Lab

Philips Signs Long-term Strategic Partnership with Oulu University Hospital Finland to Deliver Advanced Image-guided Specialist Care

April 18, 2022 – Royal Philips and Oulu University Hospital (Finland) have announced a strategic 10-year partnership ...

April 18, 2022

Philips Azurion 7 C20

News | Cath Lab

Fremont Bank Foundation Donates $750,000 to St. Rose Hospital Foundation to Enhance Its Cardiac Catheterization Laboratory Equipment

February 16, 2022 – Fremont Bank Foundation recently donated $750,000 to its community partner, St. Rose Hospital ...

February 16, 2022

Albert Cimmino

News | Cath Lab

Stabilizing Cardiogenic Shock After A Heart Attack

February 14, 2022 — A collaborative effort between The Valley Heart and Vascular Institute’s cardiology team ...

February 14, 2022

Sponsored Content | Videos | Cath Lab

VIDEO: Leveraging Analytics and Data Visualization in the Cath Lab

Advancements in analytics and data visualizations are helping to streamline operations and improve productivity at cath ...

January 13, 2022

The Philips CavaClear IVC Filter Removal Laser Sheath showing how it hooks to the filter and the laser follows the IVC structure down to where it is anchored in scar tissue. It uses a CO2 laser to dissolve the issue and release the device so it can be sheathed and removed from the body.

News | Cath Lab

FDA Clears Philip CavaClear Laser Assisted IVC Filter Removal System

January 4, 2022 — The U.S. Food and Drug Administration (FDA) has authorized marketing of the first laser-based device ...

January 04, 2022

© Copyright Wainscot Media. All Rights Reserved.